Gender-Based Operational Issues Arising From On-Demand Ride-Hailing Platforms: Safety Concerns and System Configuration

2019 ◽  
Author(s):  
Pengfei Guo ◽  
Christopher S. Tang ◽  
Yanli Tang ◽  
Yulan Wang
Keyword(s):  
System Configuration ◽  
Safety Concerns ◽  
On Demand ◽  
Gender Based ◽  
Operational Issues

scholarly journals “If You Buy a Cup, Why Would You Not Use It?” Marital Rape: The Acceptable Face of Gender Based Violence

AJIL Unbound ◽  
2015 ◽  
Vol 109 ◽  
pp. 321-325
Author(s):  
Fareda Banda
Keyword(s):  
Medical Treatment ◽  
Criminal Law ◽  
Law School ◽  
First Year ◽  
Free Access ◽  
Marital Rape ◽  
Gender Based Violence ◽  
On Demand ◽  
The Law ◽  
Gender Based

There are cases that one never forgets. DPP v. Morgan is one of those for me. I read it as an eighteen-year-old in my first year of law school. It was in the criminal law class where we were being taught about rape. The facts left me shocked and outraged. Morgan went out drinking with his friends. At the end of the night, he invited the friends back to his house. He told them that they could have sex with his wife and added that they should not worry if she appeared to resist, because she liked it that way. The friends duly came over and helped themselves to his wife as per his instructions. Morgan also forced her to have sex with him despite her protestations. She experienced injuries which necessitated medical treatment. His friends were convicted of rape, but he was convicted of indecent assault. This seemed strange. Had they all not forced her to have sex with them despite her clearly expressed refusal? Why was he charged with a lesser crime? The reason was simple: he was her husband. Under the law as it then operated in England, there was no recognition of marital rape. Her consent to lifelong sex on demand, even if it was against her will, was taken as part of the contract of marriage. The words “I do” spoken at the time of the marriage, were taken to mean free access for the husband for as long as they both lived, or until the marriage was legally dissolved or a formal separation was in place.

scholarly journals Towards Ethical International Research Partnerships in Gender-Based Violence Research: Insights From Research Partners in Kenya

2021 ◽  
pp. 107780122110357
Author(s):  
Sanne Weber ◽  
Margaret Hardiman ◽  
Wangu Kanja ◽  
Siân Thomas ◽  
Nicole Robinson-Edwards ◽  
...  
Keyword(s):  
International Research ◽  
High Income ◽  
Ethical Challenges ◽  
Gender Based Violence ◽  
Research Partnerships ◽  
Middle Income ◽  
Safety Concerns ◽  
Middle Income Countries ◽  
Gender Based ◽  
Low And Middle Income

Research with survivors of gender-based violence in low- and middle-income countries is important to improve understanding of experiences of violence and the policies that can help combat it. But this research also implies risks for survivors, such as re-traumatization, safety concerns, and feelings of exploitation. These risks are magnified if research is undertaken by researchers from high-income countries, whose positionality produces power inequalities affecting both participants and research partners. This article describes the ethical challenges of international gender-based violence research from the perspective of Kenyan researchers and organizations and identifies recommendations about how to prevent them.

scholarly journals An Empirical Study of Surveillance Anxiety

2018 ◽  
Author(s):  
Kara C. Hoover ◽  
Jeremy W. Crampton ◽  
Harrison Smith ◽  
Colette Berbesque
Keyword(s):  
Behavior Changes ◽  
Security Measures ◽  
Safety Issues ◽  
Safety Concerns ◽  
Intervention Measures ◽  
Acute Responses ◽  
Significant Divergence ◽  
Gender Based ◽  
One Year ◽  
And Behavior

We use the natural lab of music festivals to explore festival-goer views on safety concerns, intervention measures, and behavior changes in response to surveillance. By querying festival-goers, we hope to capture acute responses to rapidly introduced surveillance from one year to another. In contrast to urban spaces, where surveillance and security measures are gradually (often unnoticeably) introduced (or increased), a change from one year to the next at a festival is very obvious and usually part of the festival marketing. Specifically, we asked participants for their observations on surveillance and security measures, if those change over time, if safety concerns are addressed, and if their behavior changes. We find that festival-goers are sensitive to surveillance, with the majority of our sample reporting noticing it and those that attend more festivals observing it more. Despite that positive correlation, we did not see a bias in responses in regular festival-goers to questions about surveillance. We notice three major trends across the survey: negative crowd behavior is the most pressing issue, crowd-sourced safety measures are most valued, behavior is not altered by concerns about safety but is slightly altered in the presence of surveillance. We notice three major gender-based trends: males are less likely to report being affected by concerns or surveillance, non-binary tend to have different views than male/female respondents, females have the most concerns about safety and surveillance. Ultimately, these data uncover important issues about what makes us feel unsafe and how that varies between groups. There is significant divergence across demographics on primary safety issues. Thus, policing measures taken in everyday life have a differential negative, neutral, or positive effect depending on the member of society experiencing them. The primary limitations of our study are that the non-binary and queer subsamples are small and we did not collect ethnicity data.

scholarly journals Safety and Efficacy of Turoctocog Alfa in Prevention and on-Demand Treatment of Bleeding Episodes in Patients with Hemophilia A

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 3790-3790
Author(s):  
Dragana Janic ◽  
Irina Matytsina ◽  
Mudi Misgav ◽  
Johannes Oldenburg ◽  
Margareth C Ozelo ◽  
...  
Keyword(s):  
Research Funding ◽  
Hemophilia A ◽  
Severe Hemophilia ◽  
Open Label ◽  
Main Trial ◽  
Safety And Efficacy ◽  
Safety Concerns ◽  
On Demand ◽  
Prevention And Treatment

Abstract Background Turoctocog alfa is a B-domain truncated recombinant factor VIII (rFVIII) product for the prevention and treatment of bleeds in patients with hemophilia A. The ongoing guardian™2 trial using turoctocog alfa consists of a main trial with planned visits, a surgery subtrial for patients who need to undergo surgery during the main trial, and an on-demand subtrial based on a regulatory requirement to collect data for at least 10 patients treated on-demand for 6 months. The guardian™2 trial is an open-label, prospective, international extension to pivotal trials in adults and adolescents (aged 12-65 years; guardian™1) and children (aged <12 years; guardian™3). Patients who completed the pharmacokinetic trials (NN7008-3600, NN7008-3893, or NN7008-4015), and new patients involved in the on-demand subtrial, also participated in guardian™2. We report an analysis of new long-term safety and efficacy data from the main guardian™2 trial and on-demand subtrial of turoctocog alfa. Methods Male patients with severe hemophilia A (FVIII ≤1%) without inhibitors (<0.6 Bethesda units [BU]) were enrolled from 19 countries. Turoctocog alfa was used prophylactically (20-50 IU/kg every second day or 20-60 IU/kg three times weekly) and on-demand (20-200 IU/kg/day) to treat bleeds. The primary safety endpoint was inhibitor development (≥0.6 BU/mL). All adverse events were reported. The main efficacy endpoints included hemostatic success when treating bleeds (excluding patients with missing evaluations), number of turoctocog alfa infusions required to stop bleeds, annualized bleeding rate (ABR), and consumption of turoctocog alfa. Safety and efficacy were assessed at the interim cut-off date, March 25, 2015. Results Prophylaxis and on-demand treatment were received by 199 and 19 patients, respectively (equivalent to 589 and 12.5 years of exposure to turoctocog alfa, respectively). Turoctocog alfa was used to treat 1508 bleeds in 162 patients receiving prophylaxis, and for 320 bleeds in 19 patients receiving on-demand treatment. No FVIII inhibitors, hypersensitivity, allergic reactions, or other safety concerns were reported in the main trial or on-demand subtrial for any patients. Treatment of bleeds was successful ('excellent' or 'good' response) in 90% of patients receiving prophylaxis and in 97% of those treated on-demand; the overall proportion of bleeds stopped with 1-2 injections was 90.7%, and 95.7% taking up to three injections. The median ABR (bleeds/patient/year) was 1.48 (mean Poisson estimated ABR: 2.56) for patients treated prophylactically, and 30.3 (mean Poisson estimated ABR: 25.56) for patients treated on-demand. Mean turoctocog alfa consumption (IU/kg/year/patient) was 5335 for patients on prophylaxis and 1707 for patients treated on-demand. Mean prophylactic dose was 32 IU/kg. Mean dose for treatment of bleed from start to stop was 61 IU/kg for patients on prophylaxis and 44 IU/kg for patients treated on-demand. Conclusion The latest data from the ongoing guardian™2 trial demonstrate the long-term safety and efficacy of turoctocog alfa for the prevention and treatment of bleeds in patients with severe hemophilia A. No FVIII inhibitors or other safety concerns have been reported. Compared with on-demand treatment, prophylaxis resulted in ~3-fold higher consumption of turoctocog alfa, and a 90% reduction in bleed rates. Disclosures Janic: Pfizer: Other: Paid Instructor, Research Funding; Bayer: Other: Paid Instructor, Research Funding; Baxter: Other: Paid Instructor, Research Funding; Novo Nordisk: Other: Paid Instructor, Research Funding; Octopharma: Research Funding. Matytsina:Novo Nordisk: Employment. Misgav:Novo Nordisk: Speakers Bureau. Ozelo:Bayer: Research Funding; Baxter: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; CSL Behring: Research Funding; Biogen: Research Funding; Novo Nordisk: Research Funding, Speakers Bureau. Recht:Kedrion: Consultancy; Biogen Idec: Research Funding; Novo Nordisk: Consultancy, Research Funding; Baxalta: Research Funding. Korsholm:Novo Nordisk: Employment, Equity Ownership. Savic:Novo Nordisk: Other: Investigator. Santagostino:Novo Nordisk: Consultancy; Pfizer: Consultancy; Grifols: Consultancy; Sobi: Consultancy; Baxalta: Consultancy; Roche: Consultancy; CSL Behring: Consultancy; Kedrion: Consultancy; Octapharma: Consultancy; Biogen Idec: Consultancy; Bayer: Consultancy.

Quality management in the prophylaxis of venous thrombembolism - Results of a survey including 464 medical and surgical patients

VASA ◽  
2011 ◽  
Vol 40 (2) ◽  
pp. 123-130
Author(s):  
Klein-Weigel ◽  
Richter ◽  
Arendt ◽  
Gerdsen ◽  
Härtwig ◽  
...  
Keyword(s):  
Renal Function ◽  
High Risk ◽  
Quality Management ◽  
High Risk Group ◽  
Surgical Patients ◽  
Medical Patients ◽  
Risk Status ◽  
Vte Prophylaxis ◽  
Safety Concerns

Background: We surveyed the quality of risk stratification politics and monitored the rate of entries to our company-wide protocol for venous thrombembolism (VTE) prophylaxis in order to identify safety concerns. Patients and methods: Audit in 464 medical and surgical patients to evaluate quality of VTE prophylaxis. Results: Patients were classified as low 146 (31 %), medium 101 (22 %), and high risk cases 217 (47 %). Of these 262 (56.5 %) were treated according to their risk status and in accordance with our protocol, while 9 more patients were treated according to their risk status but off-protocol. Overtreatment was identified in 73 (15.7 %), undertreatment in 120 (25,9 %) of all patients. The rate of incorrect prophylaxis was significantly different between the risk categories, with more patients of the high-risk group receiving inadequate medical prophylaxis (data not shown; p = 0.038). Renal function was analyzed in 392 (84.5 %) patients. In those patients with known renal function 26 (6.6 %) received improper medical prophylaxis. If cases were added in whom prophylaxis was started without previous creatinine control, renal function was not correctly taken into account in 49 (10.6 %) of all patients. Moreover, deterioration of renal function was not excluded within one week in 78 patients (16.8 %) and blood count was not re-checked in 45 (9.7 %) of all patients after one week. There were more overtreatments in surgical (n = 53/278) and more undertreatments in medical patients (n = 54/186) (p = 0.04). Surgeons neglected renal function and blood controls significantly more often than medical doctors (p-values for both < 0.05). Conclusions: We found a low adherence with our protocol and substantial over- and undertreatment in VTE prophylaxis. Besides, we identified disregarding of renal function and safety laboratory examinations as additional safety concerns. To identify safety problems associated with medical VTE prophylaxis and “hot spots” quality management-audits proved to be valuable instruments.

Sign in / Sign up

Export Citation Format

Share Document